Answers are grounded in this paper and cite their sources.
Risperidone long-acting is the first atypical antipsychotic medication available in an injectable sustained-action formulation, potentially conferring the advantages of an atypical antipsychotic together with assured medication delivery. In addition, unlike depots of conventional antipsychotics composed of a prodrug in a viscous oil vehicle, this formulation uses microsphere technology to encapsulate risperidone in a biodegradable polymer. Progressive hydrolysis of the microspheres results in gradual release of risperidone leading to predictable and sustained plasma levels with repeated injections.
No takes yet. Share an insight, caveat, or question.
Pierre Chue (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: